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INTRODUCTION
Asthma is a common heterogeneous respiratory disease char-
acterized by obstruction and symptoms that are caused by air-
way inflammation and remodeling.
1 Inflammation and remod-
eling may contribute to airway hyperresponsiveness (AHR) and 
chronic airway obstruction.
2 Current therapies targeting airway 
inflammation relieve and prevent symptoms in the majority of 
patients, although some patients experience persistent symp-
toms and a progressive decline in lung function, leading to the 
development of fixed airway obstruction and excessive airway 
narrowing.
3,4 Patients with difficult-to-control asthma common-
ly take doses of inhaled therapy higher than standard doses 
and/or oral corticosteroid therapy.
3,5 From a practical stand-
point, patients whose asthma is not controlled by high-dose in-
haled corticosteroid therapy are considered to have difficult-to-
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control/therapy-resistant asthma.
3,5 Although a very small pro-
portion of the patients with asthma have difficult-to-control/
therapy-resistant asthma, these patients consume dispropor-
tional amounts of medical resources in terms of both time and 
money.
6 What underlies this decline in lung function is unclear, 
but it may reflect chronic progressive airway wall remodeling. 
The pathological features of airway remodeling include goblet 
cell and mucosal gland hyperplasia, the deposition of extracel-
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Purpose:  Severe asthma is characterized by high medication requirements to maintain good disease control or by persistent symptoms despite 
high medication use. The transfer of bone marrow-derived mesenchymal stem cells (BMDMSCs) to the injured lungs is a possible treatment for se-
vere asthma. This study investigated the therapeutic effects of BMDMSCs in airway remodeling and inflammation in an experimental toluene diiso-
cyanate (TDI)-induced asthma animal model of severe asthma.  Methods:  BMDMSCs were transferred into rats after TDI inhalation. Bronchoalve-
olar lavage (BAL) cell profiles, histological changes including an inflammatory index and goblet cell hyperplasia, and the airway response to metha-
choline using plethysmography were analyzed. Smooth muscle actin (SMA) and proliferating cell nuclear antigen (PCNA) protein expression were 
observed in lung tissue using immunohistochemical staining. The collagen content was measured in lung tissue sections and lung extracts using 
Masson’s trichrome staining and an immunoassay kit.  Results:  The numbers of inflammatory cells in BAL fluid, histological inflammatory index, 
airway response to methacholine, number of goblet cells, and amount of collagen were increased in TDI-treated rats compared with sham rats (P=
0.05–0.002). BMDMSC transfer significantly reduced the TDI-induced increase in the inflammatory index and numbers of eosinophils and neutrophils 
in BAL fluid to levels seen in sham-treated rats (P<0.05). BMDMSC transfer significantly reduced the number of goblet cells, collagen deposition, 
and immune staining for SMA and PCNA with concomitant normalization of the airway response to methacholine.  Conclusions:  The systemic 
transfer of BMDMSCs effectively reduced experimental TDI-induced airway inflammation and remodeling and airway hyperreactivity.
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lular matrix in the submucosa, smooth muscle cell hypertrophy/
hyperplasia, and hyperplasia of fibroblasts/myofibroblasts.
3,5 
The increase in airway wall thickness, collagen content, and air-
way smooth muscle mass have been associated, although in-
consistently, with asthma severity.
7-9 The possibility that remod-
eling can contribute significantly to fixed airway obstruction is 
supported by the persistence of the latter in some patients with 
severe asthma under maximal treatment that eliminates airway 
inflammation.
10 The physiological consequences of these chang-
es remain uncertain, partially because these changes are not 
fully reversed by current asthma therapy.
11,12 Therefore, devel-
oping a strategy to reverse airway remodeling is important so as 
to prevent the progressive decline of lung function in patients 
with asthma that persists despite long-term conventional treat-
ments.
In recent years, interest the stromal cell system has increased; 
this includes marrow-derived stromal cells that support hema-
topoiesis, mesenchymal stem cells and their progeny, and con-
nective tissue cells, such as osteocytes, chondrocytes, tenocytes, 
adipocytes, and smooth muscle cells.
13 Bone marrow-derived 
mesenchymal stem cells (BMDMSCs) are a group of plastic ad-
herent CD45-negative CD44H-positive cells that are capable of 
differentiating into a variety of cell types depending on culture 
conditions, including endothelial, epithelial, and neuronal cells, 
and adipocytes.
13 When BMDMSCs are infused into mice, they 
can be found in the liver, muscles, heart, intestines, and lungs, 
with phenotypic characteristics of the cells in the organ where 
they reside.
14 In the lungs, BMDMSCs have been detected as 
types I and II alveolar epithelial cells, endothelial cells, fibro-
blasts, and bronchial epithelial cells,
15 which raises the exciting 
possibility that BMDMSCs may have therapeutic potential.
After venous injection, BMDMSCs must pass through the 
lungs. Previous studies suggest higher engraftment of BMD-
MSCs into the lungs compared with other organs.
16,17 Previous-
ly, we reported that BMDMSCs engrafted at low levels when 
administered to mice challenged with bleomycin, but signifi-
cantly reduced the extent of inflammation and fibrosis in the 
lung,
13 as Ortiz et al.
18 demonstrated. This suggested a thera-
peutic strategy using BMDMSCs in patients with severe/diffi-
cult-to-control asthma. To our knowledge, however, no trial has 
examined BMDMSC transfer in experimental asthma. There-
fore, this study assessed the effects of BMDMSCs on airway in-
flammation and remodeling in a toluene diisocyanate (TDI)-
induced asthma mouse model. TDI-induced asthma results in 
chronic airways inflammation, which increases epithelial cell 
damage and airway remodeling.
19
MATERIALS AND METHODS
Isolation, purification, and maintenance of BMDMSCs
First, BMDMSCs were isolated from the bone marrow of 
Sprague–Dawley (SD) rats (Charles River Technology, Waltham, 
MA, USA) without contaminating hematopoietic cells, as de-
scribed previously.
20 Briefly, bone marrow cells were collected 
by flushing the femurs, tibias, and iliac crests of 6-week-old rats 
with phosphate-buffered saline (PBS) supplemented with 2% 
fetal bovine serum (FBS; GIBCO, Paisley, UK). The collected 
cells were cultured and maintained in T75 flasks containing 
Dulbecco’s modified Eagle’s medium and 10% FBS, supple-
mented with 100 IU/mL penicillin and 100 g/mL streptomycin 
(GIBCO). Half of the culture medium was changed at day 3 to 
remove non-adherent cells. Subsequently, the medium was re-
placed entirely each week. The cells were grown for 2–3 weeks 
until almost confluent. Then, the adherent cells were detached 
with 0.25% trypsin-EDTA. Subsequent passage and cell seeding 
was performed at a density of 1×10
6 cells. BMDMSC differenti-
ation was analyzed using flow cytometry, as described previ-
ously.
13
Intravenous infusion of BMDMSCs in a TDI-induced asthma 
model
Specific-pathogen-free, 6-week-old female BALB/c mice 
(Charles River Technology) were given 3% TDI dissolved in a 
mixture of ethyl acetate and olive oil (1:4) intranasally once dai-
ly for 5 consecutive days. Four days after sensitization, the mice 
were challenged with 1% TDI dissolved in a mixture of ethyl ac-
etate and olive oil by ultrasonic nebulization for 1 hour over 3 
consecutive days, according to a published method (Fig. 1).
13,19 
As a control group, sham mice were sensitized and challenged 
with only a mixture of ethyl acetate/olive oil. SD rat BMDMSCs 
(1×10
5 cells) were transferred to the TDI-induced asthma mice 
intravenously via tail-vein injection 1 day before the TDI chal-
3% TDI intranasal 
sensitization
Stem cell 
infusion
1% TDI 
inhalation
AHR Death
1        2        3        4        5 8 9       10      11 12          13
  
Fig. 1. 
3% TDI intranasal sensitization
1 2 3 4 5 9 10 11 12 13 8
Stem cell infusion 1% TDI inhalation AHR Death
Fig. 1.  Schematic diagram of the experimental protocol. Mice were sensitized by the intranasal administration of 3% toluene diisocyanate (TDI) once daily for 5 
consecutive days. Bone marrow-derived mesenchymal stem cells (1×10
5 cells) were transferred via an intravenous route. The following day, mice were challenged 
via the airways with 1% TDI for 3 days with 1 hr ultrasonic nebulization each day. At day 12, airway hyperresponsiveness (AHR) to methacholine was measured; 
then, the mice were killed on day 13.Mesenchymal Stem Cells in Airway Remodeling
Allergy Asthma Immunol Res. 2011 July;3(3):205-211.  doi: 10.4168/aair.2011.3.3.205
AAIR 
207 http://e-aair.org
lenge. The mice were killed on day 5 after BMDMSC transfer. 
The Institutional Animal Care and Use Committee of Soonc-
hunhyang University approved the study.
Measuring AHR to methacholine and analyzing BAL cells
Airway parameters were measured 4 days after the BMDMSC 
transfer into TDI-sensitized mice. Mice were placed in a baro-
metric plethysmographic chamber (All Medicus, Seoul, Korea), 
and baseline readings were taken for 3 minutes. The enhanced 
pause (Penh) was calculated according to the manufacturer’s 
protocol [i.e., (expiratory time/relaxation time – 1)×(peak expi-
atory flow/peak inspiratory flow)]. Penh is a dimensionless pa-
rameter that represents a function of the proportion of maximal 
expiratory to maximal inspiratory box pressure signals and a 
function of the timing of expiration.
21,22 Results are expressed as 
the percentage increase in Penh following challenge with each 
concentration of methacholine (5, 20, and 50 mg/mL). Twenty-
four hours after measuring the airway parameters, the mice 
were killed with pentobarbital sodium (65 mg/kg, i.p.), and PBS 
was infused slowly into the lungs and withdrawn via a cannula 
inserted into the trachea to obtain bronchoalveolar lavage 
(BAL) fluid. The cells in the BAL fluid were counted, placed on 
slides by cytocentrifugation, and stained using Diff-Quick (Sci-
entific Products, Gibbstown, NJ, USA). Then, the BAL fluid was 
centrifuged, and the supernatant was kept at –70°C.
Preparing lung tissue and histology and immunohistochemistry 
analysis
Trachea and lung tissues were removed from the mice. Then, 
4% paraformaldehyde fixative solution was infused into the 
lungs via the trachea. The specimens were dehydrated and em-
bedded in paraffin. For histological examination, 4-µm sections 
of embedded tissue were cut on a rotary microtome, placed on 
glass slides, deparaffinized, and stained sequentially with he-
matoxylin and eosin (H&E) and periodic acid-Schiff (PAS). The 
severity of peribronchial inflammation was graded semiquan-
titatively as previously described: 0, normal; 1, a few cells; 2, a 
ring of inflammatory cells one cell deep; 3, a ring of inflamma-
tory cells more than four cells deep.
19,23 We counted PAS-posi-
tive epithelial cells and all epithelial cells using software (Nikon 
DXM 1200; Nikon, Tokyo, Japan; and Image-Pro Plus 4.01; Me-
dia Cybernetics, Bethesda, MD, USA).
For immunohistochemistry of smooth muscle actin (SMA) 
and proliferating cell nuclear antigen (PCNA), lung tissue on 
slides was treated with 0.3% H2O2 for 30 minutes to block en-
dogenous peroxidase and then incubated at 4°C overnight with 
anti-mouse SMA goat polyclonal antibody (1:200 dilution; San-
ta Cruz Biotechnology, Santa Cruz, CA, USA) and anti-mouse 
PCNA rabbit polyclonal antibody (1:200 dilution; Santa Cruz 
Biotechnology). After the slides were incubated with an avidin–
biotin complex kit (ABC; Vector Laboratories, Burlingame, CA, 
USA), color was developed with 3,3’ diaminobenzidine (DAB; 
Zymed Laboratories, San Francisco, CA, USA).
Masson trichrome staining of lung tissue and measuring 
collagen in lung protein extracts
Lung tissues were fixed in Bouin’s solution, washed in tap wa-
ter (5 minutes at room temperature), and then stained for 10 
minutes with Weigert’s iron hematoxylin. After washing in tap 
water, the slides were stained with a mixture of 1% acid fuchsin 
and 1% Biebrich scarlet in distilled water for 2 minutes and then 
treated with 2.5% phosphomolybdic-phosphotungstic acid for 
10 minutes. Finally, the sections were stained with aniline blue 
for 1 minute, treated with 1% acetic acid for 1 minute, and then 
dehydrated in an ethanol/water series followed by five changes 
in absolute ethanol, cleared in xylene, and mounted in balsam. 
The collagen assay was performed according to the Sircol colla-
gen assay kit manual (Biocolor, Carrickfergus, Northern Ireland, 
UK). Briefly, 100 μL lung tissue protein extract was mixed with 
1 mL of Sircol dye for 30 minutes and centrifuged at 10,000 rpm 
for 5 minutes to drop the formed collagen-dye complex. After 
decanting the suspension, droplets were dissolved in 1 mL Sir-
col alkali reagent and vortexed. The acquired solution (100 μL) 
was read at 540 nm, as previously described.
13
Statistical analysis
Data are expressed as the mean±standard error of the mean. 
SPSS version 10.0 (SPSS, Chicago, IL, USA) was used. Continu-
ous data were compared using the Kruskal–Wallis test. If differ-
ences were found to be significant, the Mann–Whitney U-test 
was applied to compare differences between two samples. Dif-
ferences were considered significant when P<0.05.
RESULTS
Effect of BMDMSCs on airway inflammation in a TDI-induced 
asthma model
The BMDMSCs used in this study expressed CD44H and 
CD45 on the surface based on flow cytometry analysis, as de-
scribed previously.
13 TDI-sensitized/challenged mice had a sig-
nificantly more cells and fractions of inflammatory cells in BAL 
fluid compared with sham mice (P<0.05; Fig. 2). BMDMSC 
transfer significantly reduced the TDI-induced increase in the 
number of cells, neutrophils, eosinophils, and macrophages in 
BAL fluid to the level of that in sham-treated mice (P<0.05; Fig. 
2). On histologic examination, TDI-sensitized/challenged mice 
had a heavy infiltration of inflammatory cells and exudative 
changes in the peribronchial layers and intraluminal areas of 
the bronchi. BMDMSC transfer significantly reduced the cellu-
lar infiltration induced by TDI-sensitization/challenge (Fig. 3A). 
The semiquantitative value of the inflammatory index from 
H&E-stained images was significantly attenuated by the infu-
sion of BMDMSCs in the TDI-sensitized/challenged mice (Fig. 
3B).Lee et al.
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Fig. 2.  Cellular profiles of bronchoalveolar lavage 
(BAL) fluid. Toluene diisocyanate (TDI)-sensitized/
challenged mice had increased numbers of cells, 
macrophages, neutrophils, and eosinophils compared 
with sham-treated mice (*P<0.05). Bone marrow-de-
rived mesenchymal stem cell (BMDMSC) transfer ef-
fectively reduced the increased total cell, macro-
phage, eosinophil, and neutrophil numbers in BAL flu-
id from the TDI-sensitized/challenged mice (
†P<0.05).
Sham (n=6)
TDI (n=6)
TDI + MSCs (n=6)
T
o
t
a
l
 
c
e
l
l
s
 
(
×
1
0
-
4
/
m
L
)
60
50
40
30
20
10
0
*
†
M
a
c
r
o
p
h
a
g
e
s
 
(
×
1
0
-
4
/
m
L
)
50
40
30
20
10
0
*
†
N
e
u
t
r
o
p
h
i
l
s
 
(
×
1
0
-
4
/
m
L
)
18
15
12
9
1.0
0.5
0.0
*
†
L
y
m
p
h
o
c
y
t
e
s
 
(
×
1
0
-
4
/
m
L
)
0.25
0.20
0.15
0.10
0.05
0
E
o
s
i
n
o
p
h
i
l
s
 
(
×
1
0
-
4
/
m
L
)
3.5
3.0
2.5
2.0
0.3
0.2
0.1
0.0
*
†
A
C
B
D E
Fig. 3.  Microscopic findings of the intrapulmonary bronchi. (A) Histological examination of lung tissue. 
Lung sections were obtained from sham and toluene diisocyanate (TDI)-sensitized/challenged mice with 
or without bone marrow-derived mesenchymal stem cell transfer. Tissue sections were stained with pe-
riodic acid-Schiff (PAS) to determine the presence of goblet cells. Scale bar=200 µm. (B) Semiquantita-
tive analysis of the severity of peribronchial inflammation. All of the randomly selected histological im-
ages were scored using the inflammatory index, and the mean is presented. (C) PAS-positive cells in epi-
thelium and total epithelial cells were counted, and the percentage of PAS-positive cells was calculat-
ed. *P<0.0001, compared with the sham group; 
†P<0.0001, compared with the TDI group.
Sham (n=6)
TDI (n=6)
TDI + MSCs (n=6)
I
n
fl
a
m
m
a
t
o
r
y
 
i
n
d
e
x
 
o
f
 
t
h
e
 
l
u
n
g
6.0
2.0
1.0
0
*
†
P
e
r
c
e
n
t
 
P
A
S
-
p
o
s
i
t
i
v
e
 
c
e
l
l
s
50
40
30
20
10
0
*
†
B C
A
S
h
a
m
T
D
I
T
D
I
 
+
 
M
S
C
sMesenchymal Stem Cells in Airway Remodeling
Allergy Asthma Immunol Res. 2011 July;3(3):205-211.  doi: 10.4168/aair.2011.3.3.205
AAIR 
209 http://e-aair.org
Effect of BMDMSCs on goblet cell numbers, collagen deposition, 
and SMA and PCNA protein expression in the airways
The percentage of PAS-positive goblet cells (Fig. 3C) increased 
significantly in the TDI-sensitized/challenged mice, and the 
BMDMSC infusion significantly reduced the number of goblet 
cells to the sham level (P<0.0001). PCNA protein expression 
(Fig. 4A) markedly increased in the peribronchial muscle layer 
and in the epithelial cells in the bronchi of TDI-sensitized/chal-
lenged mice, and this was effectively reduced by BMDMSC 
transfer. TDI-sensitized/challenged mice also strongly expressed 
SMA protein in the bronchial and intraluminal exudations of 
the intrapulmonary bronchi (Fig. 4B).
To quantify collagen deposition in the lungs, Masson trichrome 
staining and the Sircol collagen assay were used. As shown in 
Fig. 5A, collagen deposition increased in the lungs from TDI-
sensitized/challenged mice, and the infusion of BMDMSCs 
into mice reduced the TDI-induced collagen deposition. The 
result concurred with the finding that BMDMSC-infused mice 
had significantly lower levels of measurable collagen than did 
the TDI-sensitized/challenged group (P<0.005; Fig. 5B), reach-
ing the normal level of the sham group.
Effect of BMDMSC transfer on the airways of a TDI-induced 
asthma model
The Penh values increased significantly in TDI-sensitized/chal-
lenged mice compared with the sham mice at 20 and 50 mg/mL 
methacholine (P<0.005 and P<0.01, respectively; Fig. 6). The 
BMDMSC infusion reduced the increased Penh values of the 
TDI-sensitized/challenged mice at 50 mg/mL methacholine to 
the level of sham controls (P<0.01; Fig. 6).
DISCUSSION
This study evaluated the effects of BMDMSCs on both inflam-
mation and remodeling in a TDI-induced mouse asthma mod-
el. TDI is a low-molecular-weight compound used widely in the 
production of polyurethane foams, automobile paint, varnish-
Fig. 5.  Histological analysis and collagen level in the lung. (A) Masson tri-
chrome stain in lung tissue of sham, toluene diisocyanate (TDI)-sensitized/chal-
lenged, and Bone marrow-derived mesenchymal stem cell (BMDMSC) trans-
ferred mice. Scale bar=200 µm. (B) Effects of BMDMSC transfer on collagen 
deposition. The total soluble collagen content in the right lung was measured 
using a Sircol collagen kit. Differences between the BMDMSC-infusion and TDI 
groups were significant. *P<0.05, compared with the sham group; 
†P<0.05, 
compared with the TDI sensitized/challenged group.
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Fig. 4.  Immunohistochemical staining of proteins expressed in the intrapulmo-
nary bronchi. (A) Smooth muscle actin (SMA) protein expression increased 
markedly in the peribronchial muscle layer of the bronchi of toluene diisocya-
nate (TDI)-sensitized/challenged mice. Bone marrow-derived mesenchymal 
stem cell (BMDMSC) transfer reduced the expression of SMA protein. (B) Pro-
liferating cell nuclear antigen (PCNA) protein expression increased markedly in 
epithelial cells in the bronchi of TDI-sensitization/challenged mice. Infusion of 
BMDMSCs reduced the expression of PCNA protein. A representative image 
from six experiments in each group is shown. Scale bar=200 µm.
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es, and related products. TDI-induced asthma may reflect a 
subtype of severe asthma.
24 Approximately 5-10% of workers in 
these settings develop occupational asthma with chronic air-
ways inflammation. Therefore, we used a TDI-induced asthma 
mouse model as a subtype of severe asthma.
In this study, the BMDMSC infusion inhibited the TDI-induced 
increase in the numbers of macrophages, eosinophils, and neu-
trophils (Fig. 2), which suggests that BMDMSCs inhibit inflam-
matory cell infiltration non-selectively. Mice exposed to TDI 
developed features of airway remodeling, including thickening 
of the peribronchial smooth muscle layer, subepithelial colla-
gen deposition, and increased airway mucus production.
12 In 
our study, SMA and PCNA stains were used to measure myofi-
broblast and smooth muscle thickening and epithelial cell 
damage and regeneration associated with remodeling. Nota-
bly, the BMDMSC infusion effectively inhibited the increased 
SMA-positive muscle layer, and PCNA-positive epithelial cells 
induced by TDI-sensitization/challenge (Fig. 4), suggesting that 
BMDMSCs effectively inhibit airway remodeling in asthma. In 
addition, the semiquantitative value of the inflammatory index 
and the percentage of goblet cells induced by TDI-sensitization/
challenge were significantly reduced after BMDMSC transfer, 
suggesting that the infusion of BMDMSCs inhibits not only air-
way inflammation, but also mucus metaplasia. The BMDMSC 
infusion significantly reduced the levels of measurable collagen 
compared with the TDI-sensitized/challenged group, indicat-
ing that the infusion of BMDMSCs can protect remodeling in 
TDI-sensitized/challenged mice.
In the lungs, many studies have reported that either whole 
bone marrow or BMDMSCs limited experimental lung injury 
and fibrosis,
13,18,25 but the idea that stem cells simply supply a 
reservoir of new lung parenchymal cells and therefore hasten 
repair is inadequate to explain the effect.
13 Although one can 
demonstrate the persistence of donor stem cells in the lungs 
and evident differentiation into lung cell phenotypes, the num-
ber of engrafted cells is too small to explain the protective effect 
sufficiently.
25 Similarly, infusions of whole bone marrow pro-
tect endotoxin-induced lung injury at a level disproportionate 
to donor cell number found in the lungs.
26 The anti-inflamma-
tory effect of BMDMSCs may be an important contributor to 
the inhibitory effect of stem cell administration.
27
The anti-fibrotic effect of BMDMSCs has been demonstrated 
in bleomycin-induced pulmonary fibrosis.
13 In the inhibitory 
mechanism of BMDMSCs, both endogenous and exogenous 
stem cells contribute to the repair process.
25 Homing of stem 
cells to injured lung is at least partly a result of the production of 
humoral mediators by injured, but not by normal, lung that are 
chemotactic for stem cells.
25 We did not evaluate the mecha-
nism of BMDMSC effectiveness, and further studies are need-
ed to clarify whether the effect of BMDMSCs is due to BMD-
MSCs or to humoral mediator release.
In summary, BMDMSC transfer effectively inhibited inflam-
mation and remodeling in a TDI-induced asthma mouse mod-
el, suggesting that BMDMSCs, which possess anti-inflammato-
ry and anti-remodeling properties, could be useful for the treat-
ment of inflammation and remodeling in severe asthma. To 
date, there has been no report on the effects of BMDMSCs on 
inflammation and remodeling in experimental asthma. This 
study is the first to establish the therapeutic effects of BMD-
MSCs in a TDI-induced asthma model.
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